Try GOLD - Free
Digital Innovations in Diabetes Care
BioSpectrum Asia
|BioSpectrum Asia Nov 2024
Diabetes affects 537 million people globally and is a major contributor to the non-communicable disease NCD) epidemic. Technological tools such as continuous glucose monitors CGMs) and mobile apps are redefining diabetes management. On this World Diabetes Day November 14, 2024), we explore how digital health is transforming diabetes care and the challenges associated with its integration into healthcare systems.
Diabetes affects 1 in 11 adults, or about 90 million people, in South-East Asia, with this number projected to rise to 113 million by 2030 and 151 million by 2045. Alarmingly, over half of these individuals remain undiagnosed. In 2021, diabetes caused 747,000 deaths in the region, and the economic burden of managing the disease reached $10 billion, as per the 2021 IDF Diabetes Atlas.
Technological advancements have proven to be a boon for diabetes care, offering various tools to help manage the condition effectively. One of the critical aspects of diabetes management is maintaining optimal glucose levels at all times. Digital health tools, such as continuous glucose monitors (CGMs), connected insulin pens, portable A1C monitors, and mobile apps, are transforming the way patients manage their condition outside of hospitals. Mobile apps enable healthcare providers to create personalised treatment plans based on real-time data.
Another innovation is the automated insulin delivery (AID) system, which integrates CGMs and insulin pumps to adjust insulin delivery continuously based on glucose data. Portable A1C monitors allow patients to measure their A1C levels at home, an essential marker for long-term diabetes management.
“Previously, patients had limited information about their condition, which led to anxiety and a lack of motivation for managing it. Now, with tools like CGMs, personal A1C monitors, and mobile apps, patients can check their levels anytime, anywhere, and easily access professional support through mobile platforms. This not only reduces uncertainty but also empowers them to receive more frequent feedback, stay motivated, and proactively manage their health. Ultimately, this leads to better health outcomes by making diabetes management more accessible and proactive,” said Yeaseul Park, Co-Founder and Co-President Orange Biomed, USA.
This story is from the BioSpectrum Asia Nov 2024 edition of BioSpectrum Asia.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM BioSpectrum Asia
BioSpectrum Asia
India Health Fund supports D-Nome to bolster molecular TB screening in India
India Health Fund (IHF), a Tata Trusts initiative, is poised to transform tuberculosis (TB) screening at scale by enabling the development of the world's most affordable molecular screening tool for TB.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
BioOra and Octane Biotech sign LoI to expand cell therapy manufacturing using Cocoon Platform
BioOra, a commercialstage cell therapy company advancing CAR-T therapies for cancer patients, & Canadabased Octane Biotech Inc., an Octane Medical Group Company, has announced the signing of a Letter of Intent (LOI) to collaborate on the co-development & deployment of advanced cell therapies using the Cocoon automated cell therapy manufacturing platform.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
NTU and NHG Health partner to advance healthcare education in Singapore
NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
Gene Solutions introduces non-invasive prenatal screening technology triSure in Taiwan
Singapore-based startup Gene Solutions has introduced triSure, a revolutionary non-invasive prenatal screening technology.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
How FemTech Spurt in APAC is Redefining Healthcare
Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.
4 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
China's Colossal Ageing Population and Low Birth Rate Challenge
China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.
2 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"
At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.
7 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area
Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"
More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.
5 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel
Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.
1 min
BioSpectrum Asia May 2026
Listen
Translate
Change font size
